MAPT and prion disease: While, as previously shown for tau, α-synuclein, and TDP-43, the presence of PrPC at the plasma membrane facilitates the uptake of pathological aggregates possibly accelerating the course of the disease, here we show that tau circulating species may protect PrPC from PrPSc interaction, thus slowing prion conversion and prion disease progression.